Prestige Biopharma Develops First-in-Class PAUF-detecting Diagnostic Kit, a Powerful Tool for Early Detection of Pancreatic Cancer

SINGAPORE, March 10 (Bernama-BUSINESS WIRE) — Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has developed a first-in-class diagnostic kit for pancreatic cancer.

Pancreatic cancer is a characteristically aggressive tumor, with an extremely poor prognosis, as shown by a 1-year survival rate of 10 to 23%, and an estimated 5-year survival rate of less than 9%¹. The low survival rates associated with pancreatic cancer are attributed to late diagnosis coupled with non-specific symptoms, early metastasis, rapid progression, and the lack of effective treatment modalities. Thus, early detection and diagnosis are crucial for improving patient outcomes and increasing survival rates.

http://mrem.bernama.com/viewsm.php?idm=45619

administrator

Related Articles